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Abstract: Vaccination has been one of the most successful and the most significant scientific 
advances in human health and life expectancy all around the globe. The World Health 
Organization considers that immunization should be recognized as the main component of human 
health right, due to the fact that vaccination prevents 2.5 million deaths annually (World Health 
Organization, 2011). The most successful vaccines have been developed using conventional 
methods that follow the paradigm established by Pasteur: "to isolate, inactivate and inject" the 
pathogen microorganism and mimic a natural infection. Recently, metagenomics have played an 
important role in the discovery of new immunogens for vaccine design and the selection of 
antigens based on genomic information. The main approach that has used this strategy has been 
called "reverse vaccinology". This promising and arising field allows the screening of the entire 
potential antigenic repertoire of an organism using predictive bioinformatic tools. Once the 
antigenic protein or proteins have been selected, they are expressed and purified using molecular 
cloning and in vitro expression techniques. Following the in vitro production step, they are probed 
in animal models to evaluate the in vivo protective strength of the immune response. The main aim 
of this in vivo approach is to evaluate the ability of the immune response to eliminate or neutralize 
the pathogen at the time of infection. Those antigens capable of generate a specific immune 
response with neutralizing activity for natural infections are the best candidate vaccines. In this 
review we summarize the evolution of vaccinology since its inception, with special emphasis on 
the development of VLPs as vaccine platforms and their future in preventive medicine and we 
introduce a new recombinant platform for antigen presentation based on Junin virus VLPs 
(JUNV-VLPs). 
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1. Introduction 
Since the discovery of the smallpox vaccine in 1796 and the origin of classic or conventional 
vaccinology, there have been numerous advances against infectious diseases. In the past, vaccines 
and therapeutic treatments were developed without the basic knowledge of the pathogenesis of the 
infectious agents. Thus, classical vaccination has been built with minimal knowledge of the complex 
immunological mechanisms by which vaccines induce protective immunity [2], [3]. 
Genomics has radically changed the identification of vaccine candidates. As a result of several 
technology revolutions, it is possible to identify new vaccine antigens using genomic, transcriptomic 
and proteomic analysis on a large scale. In addition, the advance in Bioinformatics have introduced 
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new methods for the design of antigens, and the analysis of its induced immune response [4]. 
Genomics-based technologies have also revealed novel virulence factors for various pathogens. 
1.1. Vaccinology: Pasteur's Principles and Vaccine Development 
The success of a certain vaccine depends entirely on the activation of the protective immune 
components of the organism itself. Live attenuated or inactivated vaccines have been successful 
because they mimic the type of protective immunity induced in people who has survived a natural 
infection. 
Most of the vaccines used today have been developed using conventional methods that follow 
the paradigm established by Pasteur: to "isolate, inactivate and inject" the microorganism that causes 
the disease and, thus, imitate a natural infection. In this strategy, it is important to preserve the 
following factors: 1) reducing or eliminating the infectivity of the pathogen (attenuation and/or 
inactivation), 2) inhibiting its ability to replicate, 3) preserving their immunogenicity.  
Pasteur applied his principles to viruses (rabies viruses isolated from rabbits), and bacteria 
(heat-inactivated anthrax bacilli) with great results. However, these approaches have been 
successful so far for those pathogens with invariant antigens, and those that after a single infection 
can induce an immune memory capable of preventing subsequent re-infections, such as smallpox, 
yellow fever, poliomyelitis, rabies, Mumps, measles, rubella, varicella, herpes zoster, hepatitis A, 
and Japanese encephalitis [5]. In addition, attenuated inactivated or live vaccines have also been 
developed against some infectious bacterial diseases with different successfulness; the 
Calmette-Guerin Bacillus (live attenuated Mycobacterium bovis) is possibly the most widely used 
vaccine and is currently the only available against tuberculosis [6]. 
However, classical or conventional vaccination has proven to be inadequate in the development 
of vaccines against pathogens with different characteristics: a) pathogens antigenically diverse; b) 
pathogens that cannot be grown in vitro; c) pathogens lacking adequate animal models of infection; 
and d) pathogens that stimulate cell-dependent immune response (T cells). 
These difficulties were solved with the development of subunit vaccines based on Pasteur's 
strategy: essential components of the pathogen, usually virulence determinant subunits, were 
isolated and inactivated to be used as vaccines. This approach was first applied for diphtheria and 
tetanus. At the present, subunit vaccines have grown significantly and their ability to generate 
long-term immune responses and immune memory has been optimized. These types of vaccines are 
safe and effective, and multivalent formulations have been developed, for example, to provide 
protection against numerous pneumococcal serotypes and meningococcal serogroups in a single 
shot. 
Although the virtual disappearance of diseases such as diphtheria, tetanus, whooping cough 
and Haemophilus influenzae type b are references for the success of vaccines, there are still many 
diseases where vaccination strategies have not been successful so far. This is due not only to the 
hypervariability of their antigens but also to an incomplete understanding of pathogenicity 
mechanisms and cell-mediated immune responses [7]. A clear example is HIV (human 
immunodeficiency virus), an infection that stimulate a virtual adaptive humoral immunity, and 
therefore, vaccines must induce cellular immunity with low or lack of protective potential over time 
[8], [9]. 
Recombinant techniques to develop subunit vaccines and genetic inactivation by targeted 
mutagenesis, has made possible to generate attenuated live vaccines and safer subunit vaccines 
through the design in silico. This technology has also generated a wide range of new platforms 
vaccines and ways of administration. Recombinant antigens from a subunit vaccine are usually 
better tolerated than live attenuated or inactivated pathogens or purified "natural" subunits for 
vaccination. This is because they are produced in cell cultures from the natural host and their 
proteins exhibit identical posttranslational modifications to those present in wild type infectious 
virions lacking other viral immunogens that might generate inflammation or unspecific immune 
response. However, the main limitation is the low immunogenicity that might result in the addition 
of an adjuvant to generate a protective immune response [10]. 
1.2. Reverse vaccinology 
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Genome-based antigen selection has played an important role in the discovery of new 
immunogens for vaccine design in the past years. The use of these approaches has been called 
"reverse vaccination" and has enabled the screening of the whole potential antigenic repertoire of an 
organism through its genome using bioinformatic predictive tools [11]. 
Reverse vaccinology involves the in-silico prediction of proteins with immunogenic 
characteristics from the genome of a pathogen organism using bioinformatic methods. The predicted 
proteins are expressed recombinantly as surface antigens or secreted in monomeric or oligomeric 
forms to be purified using in-vitro molecular cloning methods and evaluated in animal models to 
test their ability to generate a protective immune response. Those antigens capable of generating a 
specific immune response with neutralizing activity for future natural infections are the best 
candidate vaccines. 
This approach has been applied to a wide range of pathogens and has provided a long list of 
antigens whose functionality was unknown [12]. Further studies on the function of each antigen also 
allow a better understanding of the biology of pathogens. One example is the use of protective 
antigens implicated in bacterial adhesion, as there may be important implications for providing 
immunity by reducing colonization and circulation of the pathogen. In fact, functional studies of 
many protective antigens have subsequently revealed that they are new adhesins involved in the 
colonization of the pathogen[13], [14]. 
Although a vaccine antigen does not necessarily have to be a virulence factor; focusing on 
proteins with a crucial role in pathogenesis or survival is a useful selection criterion since the 
antibodies induced against this type of antigens can block their function and result in the general 
neutralization of the pathogen. 
The first pathogen in which reverse vaccination was used was Neisseria meningitidis serogroup 
B [15]. Pizza and colleagues identified 29 new antigens that could induce a bactericidal humoral 
response against the pathogen in vitro. Studies performed on three of the major antigens included in 
the MenB vaccine (Neisseria heparin binding antigen, NHBA, factor H binding protein, fHbp, and 
adhesin A, NadA) have subsequently been reported as important factors of virulence in 
meningococcal infection [13]. Several advances have been made since this first application of reverse 
vaccination. In 2005, Maione and colleagues [16] applied a "multi-genome or pan-genome reverse 
vaccinology" approach to streptococcus group B to identify antigens from the complete gene pool of 
the species rather than a single organism; more recently the "subtractive reverse vaccination" 
approach has been implemented to identify antigens present in non-edible pathogenic strains of 
Escherichia coli [17]. 
1.2.1. Rational design of vaccines 
Currently, the main application of reverse vaccination is the rational design of candidate 
vaccines. The rational design follows a stepwise approach (Figure 1): 1) identification of a target 
antigen, 2) selection of a vaccine platform, 3) optimization of factors for gene expression, 4) 
production and characterization of the candidate vaccine, and finally 5) analysis of the biosafety, 
immunogenicity and efficacy cellular models in vitro and in animal models [18]. 
In virology, recent advances in molecular biology and bioinformatics have contributed 
significantly to the understanding of the structure, replication, attenuation and pathogenicity 
determinants. The knowledge of these aspects is crucial to identify target proteins [18]. 
Computational vaccinology is the field that focuses on the process of antigenic identification in a 
predictive manner. Most of the bioinformatics tools focus on the presentation and processing of 
antigens and try to aim the response towards T and B cells. Although the mapping and identification 
of highly immunogenic epitopes on target antigens is important, several additional steps should be 
considered when designing new vaccines rationally. 
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Figure 1. Rational design of candidate vaccines approach. The rational design of candidate vaccines 
can be easily summarized in the three conventional stages: during the in silico stage every 
identification and selection is made using bioinformatic tools; the in vitro stage consists of the 
molecular cloning of the selected sequences into the expression vector, the protein expression and its 
analysis; finally, the results obtained in the in vivo stage will determine the use of the selected 
candidate. 
1.3. Structural vaccinology and virus-like particles (VLPs) as vaccine platforms 
Structural vaccinology is an emerging discipline that aims to identify, design and evaluate 
antigens with vaccine potential based on studies of structural biology, computational biology, 
immunology and serology [19], [20]. This emerging field also uses transcriptomics and 
proteomics tools that can inspect the set of antigens expressed by a pathogen under specific 
conditions, examining the mRNA and the proteins of an organism, respectively. Moreover, the 
analysis can be focused only on one subset of proteins: those exposed on the surface (surface 
proteome) or those functionally important for infection (functional genomics) [4]. There are also 
new fields of study focused on elucidating the set of antigens that interact with the host's 
immune system and the mechanisms involved in these interactions (immunomics) as well as 
the way in which the immune system responds to a vaccine (vaccinomics). While each of these 
approaches has limitations, they have all emerged as powerful tools in the development of 
vaccines and are directly linked to structural vaccinology. 
Although the technology improvement and the fact that modern vaccines contain safer antigens, 
the levels of protective immunity induced are lower when compared to nineteenth and early 
twentieth century vaccines. 
One approach that attempts to overcome this disadvantage is the use of virus-like particles 
(VLPs) [21]. VLPs have the same repeatability, geometry, size and morphology of natural 
virions and lack the original viral genome. These VLPs can be composed of single or multiple 
antigens, in some cases anchored in a lipid bilayer and are generated by the self-assembling 
activity of some structural proteins of different virus. VLPs are used as platforms for the 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 25 January 2020                   doi:10.20944/preprints202001.0294.v1
 5 of 13 
 
presentation of immunogenic epitopes: the pIII protein of filamentous phage f1 [22], the Ty 
component of Saccharomyces cerevisiae [23], the surface or layer proteins of the bluetongue 
virus (BTV) [24], the human parvovirus B19 [25], the tobacco mosaic virus (TMV) [26] and the 
human papilloma virus (HPV) [27] are some examples. 
The rational design of vaccines combined with structural vaccinology and the emerging of 
self-assembling VLPs are currently the most promising field to develop generic vaccine 
platforms and there are currently available several VLPs-based vaccines [28]. 
1.3.1. VLPs: impact on vaccinology 
VLPs are self-assembling supramolecular associations that do not carry any genetic information, 
are non-replicative and can be produced in heterologous expression systems. VLPs are biosafe 
given the lack of genetic information and that they preserve the immunological characteristics 
of the original virus that induce immune response [29] Furthermore, due to the fact that many 
antigens can be exposed on the surface of VLPs, they are powerful tools in immunology and 
vaccinology since they can be used as vaccine platforms and therapeutic delivery systems [30]–
[33]. It has been reported that VLPs stimulate the immune system completely, they: a) stimulate 
innate immunity through Toll-like receptors (TLRs) and pattern recognition receptors (PRRs) 
due to the expression of multivalent and repetitive structures; b) induce a strong humoral 
response and IgM in T-cells independently; and c) increase affinity by enhancing the 
maturation of APCs (Antigen Presenting Cells), and processing and presentation by the APCs 
through the route of the MHC-I and MHC-II (Major Histocompatibility Complex class I and 
class II) due to their particulate nature [34]. 
1.3.1.1. Structure of the VLPs 
VLPs have been generated from a large number of anthroponotic and zoonotic viruses [32], 
[35]–[37]. They are composed of one or more structural or capsid proteins capable of 
self-assembly into virion-like morphological structures. Compared with complete virions, they 
do not replicate or infect host cells due to the absence of genetic material. In addition, it has 
been reported that they can be used as vaccines without artificial adjuvants [38], [39]. 
The structural proteins responsible for the generation of VLPs vary depending on the biology of 
the virus: a) simple viral capsids with one or two major structural proteins (Parvovirus, HPV, 
Circovirus, Calcivirus, hepatitis E virus (HEV) and Poliomavirus); b) complex viral capsids 
with several layers of viral proteins encoded by different mRNAs or generated from a single 
polypeptide (Rotavirus, Picornavirus), or c) enveloped viral capsids derived from the host cell 
membrane that may include surface glycoprotein spikes (Influenza, HIV, hepatitis C (HCV) and 
arenavirus [40]. 
Recently, there has been described viral nanoparticles (VNPs) and VLPs derived from plant 
viruses [35]. 
1.3.1.2. Processing of VLPs by the immune system 
VLPs are commonly more immunogenic than subunit immunogens or recombinant proteins 
and are capable of stimulating both the humoral and cellular immune responses [41]. VLPs can 
be inoculated subcutaneously, intraperitoneally or intramuscularly. Their small diameter 
facilitates the entry into the lymphatic system and drains directly to local nodes. Once in the 
lymph node, the VLPs are processed mainly by dendritic cells (DCs); the capture mediated by 
the DCs is improved by the shape and size of the VLPs, identical to those of the infectious 
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virions. Once processed, they stimulate the activation and proliferation of T-CD4+ cells through 
the MHC II and the MHC I pathways and induce innate immunity. 
1.3.1.2.1. Induction of innate immunity  
In some cases, VLPs do not require the use of adjuvants to achieve efficient immune stimulation. 
The self-adjuvant effects are inherent to their adequate size; this facilitates their uptake by the 
DCs, their subsequent processing and presentation by MHC class II, and the promotion of the 
maturation and migration of DCs, essential for the innate immune response [42], [43]. VLPs can 
also be captured and processed through the MHC class I pathway (cross-presentation) to 
achieve the activation of T-CD8 + cells, essential for the elimination of intracellular pathogens. 
The ability of VLPs to aim the DCs is an important advantage of VLP vaccines since it is now 
understood that these cells are essential to initiate both innate and adaptive immune responses. 
On the other hand, the VLPs that retain their receptor binding regions are able to enter cells 
through their regular cellular receptor and are captured afterward by APCs as exogenous 
antigens. It has been shown that receptor-mediated uptake occurs in paramyxoviruses and in 
HIV [44], [45]. In the case of the stimulation of DCs to produce cytokines, such as interferon-α / 
β, it does not require the virus replication, but an intact envelope of an inactivated virus [46] or 
a non-enveloped VLP, as in the HPV-VLPs [47]. In this context, VLPs may have very important 
advantages over attenuated viruses for immune activation, because several viruses that 
replicate in DCs impede their activation and maturation through the expression of particular 
viral proteins. [48]. 
1.3.1.2.2. Induction of adaptive immunity 
In order to induce humoral immunity in higher antibody titers, the target antigens could be 
exposed on the surface of the VLPs at high densities. VLPs imitate the structure of the native 
virions and have a spatial structure that allows the correct detection of the conformational 
epitopes, and consequently they increase the production of neutralizing antibodies. This is 
especially important for surface proteins, where enveloped VLPs allow proteins to appear in 
their natural state as membrane-anchored proteins, rather than soluble ectodomains [49]. 
Hence, VLPs can offer a safe and effective approach for the induction of antibodies by surface 
proteins where the soluble forms have not been effective [35]. Some VLPs have also the ability 
to present multiple proteins to the immune system. For example, the successful hepatitis B virus 
(HBV) vaccine has been optimized by including two other envelope proteins in the HBsAg 
particle, thus mimicking the authentic virion envelope that contains these three proteins. HBV 
vaccines that include these additional envelope proteins stimulate the production of antibodies 
differently and more specifically due to the provision of additional T cell epitopes that promote 
a more complete α-HBsAg response and improve the rate of seroprotection [50]. 
Another important example is HIV. Great efforts have been made to recreate the virion 
envelope that allows efficient induction of neutralizing antibodies. VLPs were produced in the 
form of synthetic proteoliposomes in solid microspherical beads in order to mimic the lipid 
membrane for the presentation of the HIV glycoprotein GP160 [51], as well as VLPs mimicking 
the HIV particle containing the envelope proteins associated with its matrix protein Gag [52]. 
This, in addition to the advances made by reverse vaccinology, has helped the understanding 
that the key domains associated with viral entry and conserved regions probably do not 
experience antigenic variation despite neutralizing immunological pressure. Recently, the 
research has focused on the presentation of highly conserved and neutralizing epitopes of the 
envelope protein GP41 of HIV-1 in a pre-fusion conformation, which is only briefly exposed 
during viral entry [53]. 
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1.3.2. VLPs as vaccine platforms 
VLPs can be used as potential vaccines against the original viruses as well as displaying 
platforms for foreign individual epitopes. This can be done by gene fusion and subsequent 
expression of the resulting recombinant protein or by chemical conjugation between the target 
antigen and the structural protein that generates the VLPs, offering new perspectives in the 
development of vaccines [21]. 
One of the best achievements of VLPs as vaccine platforms is the vaccine against malaria, a 
chimeric and recombinant VLP (rVLPs) made of the circumsporozoite protein of Plasmodium 
falciparum and the surface antigen of hepatitis B virus. This candidate vaccine, called RTS-S, 
has reached phase III clinical trials and induces a protection of approximately 30-50% [54]. 
Despite this moderate efficacy, which can be explained by the low expression of the antigen on 
the surface of the VLPs, the RTS-S is the first vaccine that shows significant protection against 
malaria, where other strategies such as synthetic peptides and viral vectors have failed so far. 
Likewise, other platforms have been used to display foreign antigens. Using simple structures 
made up of self-assembling proteins such as the HBcore protein, the envelope protein of the 
alfalfa mosaic virus, the HPV L1 protein or the bacteriophage Qb, has been shown to effectively 
stimulate specific immune responses against displayed antigens [55]–[57]. The structural 
proteins are crucial because they influence the overall immunogenicity. These studies 
demonstrate the great potential of the rVLPs since many of them have already reached the 
phase of clinical trial [36]. The rVLPs derived from enveloped viruses also offer an encouraging 
panorama to integrate target antigens on their surface and anchored in their membrane. 
Another viable strategy for antigenic displaying is pseudotyping, in which pseudo-viral 
particles are decorated with foreign antigens using genetic engineering. It is important to 
highlight that pseudoviruses, unlike VLPs, are complete viruses that carry foreign proteins that 
are not encoded in their genome, providing extra functions during infection that will not be 
present in the viral progeny. This approach has two important advantages: a) displaying the 
foreign antigens in its native conformation and, b) optimization in the uptake by the APCs. 
Retroviral nuclei have been shown to be adaptable for this approach. retroVLPs based on 
simple oncoretroviruses (retrovirus-like particles) have been developed using the retrovirus of 
murine leukemia (XMRV, Xenotropic murine leukemia virus). The expression of the matrix 
protein Gag is sufficient to generate enveloped pleomorphic particles of 80-120 nm, which can 
be pseudotyped with different proteins without weakening its functionality, such as 
glycoproteins of the lymphocyte choriomeningitis virus (LCMV), the virus of splenic necrosis 
(SNV), the vesicular stomatitis virus (VSV), the HCV, the virus of the Yellow fever (YFV), West 
Nile virus (WNV), Influenza virus, HIV or cytomegalovirus (CMV) [58], [59], without weakening 
its functionality. 
1.4. Current developments in Junín virus’ virus-like particles (JUNV-VLPs) 
In our laboratory we generated JUNV-VLPs in HEK-293T cells and we were able to evaluate the 
immune response in mice [60], [61]. The plasmid vector pZ-GFP includes the sequences of the 
JUNV matrix Z protein and GFP. These VLPs were able to induce humoral response in mice 
and we are currently analyzing the qualitative induction of the cellular response. Based on 
these results and on the interaction between the Z protein and the other proteins of the virion, 
we designed and developed a plasmid that allows the heterologous expression of foreign 
antigens anchored to the JUNV-VLPs membrane. The design includes the minimum genomic 
elements of anchoring and membrane targeting of the JUNV glycoprotein complex GP-C and 
the cytosolic domain that interacts with Z to ensure their incorporation into the VLPs [62]. This 
vector was named pResAg, for presenting antigens plasmid (Figure 2). Although we have been 
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able to clone different viral antigens in pResAg (the ectodomain of the measles virus 
hemagglutinin and the Saint Louis virus NS1 protein) and we have detected their correct 
expression with specific antibodies [62], the validation of the model is being carried out with the 
eGFP indicator protein due to its obvious fluorescent advantages and for its properties of 
conferring stability to the heterologous proteins that include its sequence. These trials, together 
with the inoculation of laboratory animals and the evaluation of the immune response 
generated in vivo, will allow us to evaluate the ability of pResAg to be used as a future vaccine 
platform. 
 
Figure 2. Genetic engineering of the expression vector pResAg. Top- Schematic representation of the 
GP-C sequence and the selection of its minimum elements, and the virion membrane as well as the 
membrane of a mammal cell expressing “ResAg”; Bottom- Details of the ResAg ORF (red arrow); 
GP-C: glycoprotein complex; SSP: stable signal peptide; G1: glycoprotein 1; G2: glycoprotein 2; MCS: 
multiple cloning site; Ag: antigen. 
1.5. Limitations of VLP-based vaccines 
As described above, VLPs can be considered antigen presentation systems that induce powerful 
and broad immune responses against several target antigens. VLPs are also biosecure and have 
immunogenicity advantages over the traditional approaches. There is a clear trend towards the 
use of VLPs as platforms for the development of many prophylactic vaccines. However, there 
are technical and practical considerations that may limit the application of VLP vaccines. First, 
due to its particulate nature, vaccines based on VLPs can only be effective against specific B or T 
cell epitopes that are highly conserved. Many pathogens undergo antigenic variation in 
response to host immune pressures during the course of infection and VLPs would not induce 
long-lasting immune responses against variant antigens. Secondly, considering immunological 
stress or the low rate of biodegradability, the possible toxicity of VLPs in the organism should 
not be ignored. Toxicity studies should be designed to maximize the detection of toxic effects 
resulting from the primary or secondary pharmacological action of VLP vaccines [49]. Finally, 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 25 January 2020                   doi:10.20944/preprints202001.0294.v1
 9 of 13 
 
not all viruses can produce VLPs and some of those capable of generate VLPs cannot be used as 
vaccine candidates. Last but not least, pre-existing or maternal antibodies against VLPs can 
adversely affect immunogenicity, which would result in a failure vaccination [63].  
2. Discussion 
VLP technology is a rising field thanks to the areas of molecular biology and structural biology. 
VLPs of zoonotic viruses generated by structural elements of mature virions have received 
considerable attention during the last two decades. In fact, the data collected from the field 
suggest that VLPs are more effective than many other types of subunit vaccines against 
different infectious diseases. Recently, therapeutic vaccines based on VLPs have been 
developed with the aim of inducing humoral response against molecules that are involved in 
pathologies or chronic processes [63]. After these human vaccines based on VLPs were 
evaluated clinically, several important goals have been achieved: the reduction of blood 
pressure in hypertensive patients, the improvement of smoking abstinence after inoculation 
with a nicotine vaccine [64] and high antibody titers and cellular immune response against 
Plasmodium falciparum [65], . Also, to facilitate preliminary clinical trials, new non-clinical 
study programs have been developed [49]. The therapeutic vaccines can also be applied in the 
veterinary field to alleviate the suffering of animals with chronic diseases that cannot be 
sacrificed considering animal welfare. 
Finally, numerous successful cases have been reported and new applications to VLPs continue 
to be described, being the VLPs-based vaccines the most promising field in preventive medicine 
during the 21st century. 
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